Dainippon Sumitomo Pharma shifts the focus back to its core business

Dainippon Sumitomo Pharma puts PE investment aside for now.

Dainippon Sumitomo Pharma is currently allocating JPY8.8 billion to private equity investment, representing 3.6 percent of its portfolio.

It expressed that, in the near future, it will not actively look for PE investments as it wants to allocate more resources for the in-house product development and its core business.

Platinum subscribers may click here for the Dainippon Sumitomo Pharma's full profile, including key contacts, allocation strategy and fund investments.